Articles tagged with Breast Cancer
Researchers have purified the protein produced by the breast cancer susceptibility gene BRCA2, opening new possibilities for understanding, diagnosing, and treating breast cancer. The protein plays a role in repairing damaged DNA, acting as a mediator to help another protein associate with a single strand of DNA.
A phase 3 trial found trastuzumab improves median survival to 13.8 months for HER2-positive advanced gastric cancer patients, with a 26% reduction in death rate compared to chemotherapy alone. The treatment's cost effectiveness is questioned due to its estimated £13,857 per patient cost and $55,000 cost per life-year gained.
A recent study led by University of Alberta researcher Margie McNeely found that only five percent of breast cancer survivors are at risk of developing arm swelling due to air travel. The research involved 60 Canadian women who flew to Australia and showed that 95% had no arm swelling.
Indiana University-Purdue University Indianapolis researchers have developed a new methodology to improve identification of breast cancer tissue by pathology laboratories. Their work, recognized internationally, has been selected as the best scientific paper in the
Scientists have discovered an accomplice in breast cancer – a master control switch with the power to set off a cascade of reactions orchestrated by a cancer-causing gene named Wnt1. The executive molecule MTA1 is reported to trigger cancer-causing signals from Wnt1 in human breast cancer cells, leading to tumors.
A recent study by University of Alberta research fellow Amy Speed-Andrews found that Iyengar yoga improved physical and mental health in breast cancer survivors. The 10-week program showed significant reductions in stress, anxiety, and depression, with participants experiencing improvements in quality of life and overall well-being.
A newly formed advisory committee will review all federal breast cancer research efforts and develop recommendations for improving existing programs. The committee aims to expand opportunities for collaborative, multi-disciplinary research and advance the understanding of links between environment, genes, and health.
Researchers at the University of Gothenburg have identified 12 genes linked to aggressive breast cancer, which could lead to more reliable prognoses and better treatment strategies. The study found that these genes are associated with an increased risk of tumor progression, cell growth, motility, and development.
A recent study suggests that a new drug, Olaparib, can reduce tumor size in women with advanced hereditary ovarian and breast cancers, offering a promising targeted therapy approach. The Phase II trials showed significant shrinkage in tumor size and relatively mild toxicities.
Researchers compared four progestins and found that N-EL and N-One strongly inhibited tumor development, while MPA promoted it. Progestins like N-EL and N-One may have potential as preventive agents in women with no breast disease or family history.
Researchers develop a new method to target cancer tumors using heat and magnets, reducing side effects and damage to healthy tissue. The innovative technique uses biomarkers attached to individual tumors and excites nano-particles with an external magnetic field, killing the tumor cells.
A researcher is studying a gene that may contribute to aggressive breast cancer. If successful, the study could lead to new treatments for the disease.
A Kansas State University research team is investigating the mutated ADAM12 gene's role in breast cancer, with findings suggesting its high expression in cancer stem cells. This discovery could lead to more targeted therapies, as conventional treatments often fail on these aggressive cells.
Researchers at Wake Forest University Baptist Medical Center found that low ferroportin levels are associated with aggressive and recurring breast cancers. Testing ferroportin levels may help predict cancer return and guide therapy for patients.
Researchers found that African American women who use oral contraceptives are more likely to develop estrogen receptor negative breast cancer. The study, based on data from the Black Women's Health Study, also revealed a significant increase in risk for women who have used oral contraceptives for 10 or more years.
Researchers developed an alphavirus vector to overcome neutralizing antibodies and induce immune responses in humans with advanced cancer. Genetic mutations determined breast cancer subtype by influencing Rb gene expression.
Researchers found that epigenetic profiles of tumors had a direct association with diet, alcohol, and tumor size, providing new biomarkers for disease subtype and severity. The study's data show promise for tumor epigenetic signatures to provide more detailed tumor staging and prediction of prognosis.
A study led by researchers at the University of Louisville found that individuals with a male first-degree relative with breast cancer perceive themselves as being at higher risk than those with a female relative. However, many lack awareness and discussion about genetic testing.
A study published in JAMA found that a genetic risk score is strongly associated with an increased risk of breast cancer and can predict the type of disease. The researchers identified specific genes that have different effects on different subtypes of breast cancer.
A team of researchers led by Dr. Kerry Courneya will investigate the impact of physical activity on breast cancer outcomes in a five-year study. The study aims to explore how physical fitness levels affect disease recurrence, treatment completion, and quality of life in women with breast cancer.
A study found that mammographic tumor detectability decreases with age, primarily due to denser breast tissue masking tumors. The study suggests that lowered mammographic tumor detectability accounts for 79% of the poorer sensitivity in mammography screening among younger women.
The Marilyn B. Gula Mountains of Hope Foundation has donated $50,000 to the Translational Genomics Research Institute (TGen) for advanced breast cancer research and treatment. The donation will support groundbreaking research into the genetic components of common and complex diseases, including advanced breast cancer.
The GRB7 gene is found to drive an aggressive form of breast cancer and acts independently of the HER-2 gene. Isolating its role could help fine-tune treatment and enable accurate prognoses.
Researchers found that African women are more likely to develop triple-negative breast cancer, a condition characterized by the absence of estrogen and progesterone receptors. The study suggests that African ancestry may be associated with a higher risk of hereditary predisposition for breast cancer related to BRCA1 gene mutations.
Researchers found that women who used more air fresheners and products for mold and mildew control had a higher incidence of breast cancer. The study suggests that cleaning products may contribute to breast cancer risk, highlighting the need for further investigation into this potential link.
A three-year clinical study will examine the relationship between physical function decline and age-related disparities in breast cancer treatment. The study aims to develop a well-validated instrument for measuring functional decline among senior adults with cancer, ultimately improving breast cancer outcomes for older women.
Two new studies have tested three different methods for accurately measuring breast density. A third technique called dual-energy mammography showed promise in measuring breast density. The researchers hope to use this method to improve the accuracy of breast cancer risk assessments.
A study analyzed the probability of surviving nine types of cancer in Spain, comparing rates to European averages. The results show varying survival rates for different cancers, with some types having high recovery rates (e.g., testicular and skin melanoma) while others have lower rates (e.g., lung cancer).
Researchers at Northwestern University developed a new arsenic nanoparticle that effectively targets and blocks aggressive triple negative breast cancer. The nanoparticles deliver the toxic cargo directly to tumor cells while shielding normal tissue from harm, making it a promising lead for improving chemotherapy drugs.
The Samuel Waxman Cancer Research Foundation has awarded 13 collaborative and 3 individual research grants worth $1.54 million to top scientists exploring cancer differentiation therapy. The recipients are experts in reprogramming cancer cells, with a focus on finding new treatments for various types of cancer.
The European Society for Medical Oncology (ESMO) has published updated clinical practice guidelines for cancer care, providing vital information on diagnosis, treatment plans, and follow-up. The new guidelines cover various tumor types and include expanded sections on cardiotoxicity and fertility considerations.
Researchers have successfully induced epigenetic reprogramming in human and mouse breast cancer cells, making them more susceptible to tamoxifen treatment. This targeted epigenetic therapy has shown promising results in reversing the growth and invasive properties of triple-negative breast cancer cells.
The article discusses a new approach to breast cancer detection using microwave tomography, which is cheaper and less invasive than traditional X-ray mammography. The method uses mathematical models to reconstruct images of the breast based on electrical conductivity properties.
Two phase-2 trials demonstrate the efficacy of olaparib in treating advanced ovarian and breast cancer in patients with BRCA1 or BRCA2 mutations. The higher dose of olaparib showed better treatment response rates compared to the lower dose, with ORR of 33% and 41% respectively.
A new therapy called olaparib has shown promising results in slowing tumor growth in advanced breast cancer patients with a genetic mutation. The treatment was found to be effective in 85% of patients, with fewer side effects compared to traditional therapies.
A large-scale study involving over 7,700 participants found a positive association between DNA polymorphisms related to estrogen production and breast cancer development. The research suggests that combining multiple genetic markers can estimate breast cancer risk and may lead to the development of new prevention and treatment strategies.
Researchers found that virgin olive oil decreases oncogene p21Ras activity and stimulates tumour cell death, while also preventing DNA damage. This study provides new insights into the protective role of virgin olive oil against breast cancer.
Researchers at Ohio State University discovered how dietary supplement indole-3-carbinol (I3C) blocks cancer cell growth by destroying the Cdc25A molecule. I3C reduced tumor size by up to 65% in breast cancer models, offering potential health benefits and a new strategy for cancer treatment.
The authors propose a new paradigm for breast cancer screening, shifting focus from mammography to more effective early detection methods. Behavioral interventions appear to have limited impact on repeat screening rates, and media attention highlights the flaws of current technologies.
A new study found that nearly 49% of women with early-stage breast cancer did not complete their full hormone therapy regimen. Younger women were more likely to discontinue treatment. The study highlights the need for better understanding and interventions to reduce treatment non-compliance.
A four-year clinical trial will investigate the effects of weight loss and increased physical activity on quality of life and co-existing medical conditions in overweight breast cancer survivors. The study aims to reduce breast cancer recurrence risk and improve psychosocial problems.
African-American women have more advanced breast cancer at diagnosis and poorer survival outcomes compared to non-Hispanic whites. Despite similar surgical care and adjuvant therapy, African-Americans experience lower overall and breast cancer-specific survival rates due to socio-demographic factors.
Menopausal hormone therapy may offer significant benefits to some women, particularly those starting treatment a short time after menopause. The Endocrine Society's new statement suggests that MHT can lead to a 30-40% decrease in mortality and a 90% reduction of menopausal symptoms.
A recent study found that women taking tamoxifen for early-stage breast cancer are more likely to carry a gene mutation for clotting if they develop blood clots. The Factor V Leiden genetic mutation is associated with increased thrombosis risk in these patients.
A study published in the Journal of Advanced Nursing found that specially trained nurse practitioners detected the same breast abnormalities as consultant surgeons in 92% of cases. The research aimed to test the theory that trained nurse practitioners can perform an important role in assessing new patients with symptomatic breast cancer.
Researchers have discovered that peach and plum extracts induce the death of breast cancer cells without harming normal cells. The compounds chlorogenic and neochlorogenic were found to be responsible for this differential effect.
A study published in The Lancet Oncology found that zoledronic acid reduced the number of tumor cells in bone marrow at surgery and improved bone density in women with stage II or III breast cancer. The treatment may also help fight certain types of breast tumors directly.
Researchers at the University of Pennsylvania School of Medicine have made significant progress in treating metastatic breast cancer, using a targeted immunotherapy approach that boosts the effectiveness of a therapeutic vaccine. The treatment has shown rapid and marked loss of Tregs without toxicity, resulting in stabilization of dise...
Cancer patients can benefit from moderate-intensity aerobic exercise, tailored to individual needs, to improve quality of life, muscular strength, and reduce the risk of recurrence for breast cancer patients. Exercise also helps maintain lean body mass, contributing to increased well-being.
A large UK study found that genetic variations associated with an increased risk of breast cancer do not interact with environmental factors such as hormone replacement therapy, age at first birth, or obesity. The study's authors conclude that genetic and environmental risks for breast cancer are independent.
Research reveals genetic variations that affect estrogen levels and inflammation, leading to joint pain in breast cancer survivors on aromatase inhibitors. The study identifies personalized strategies to boost compliance and offers new treatment options for this debilitating side effect.
Women who have had a bilateral oophorectomy tend to have smaller tumors and have their tumors detected by mammography rather than physical exam. However, hormone therapy after surgery wipes out any difference in tumor size or detection method.
Researchers at Yale University found that prenatal exposure to BPA and DES can increase an offspring's risk of breast cancer. The chemicals, known as endocrine disruptors, alter gene expression in the breast throughout life, leading to a higher risk of breast cancer in adults.
Researchers found that inflammasome activation increases muscle damage in muscular dystrophy, while galectin-7 expression levels are associated with metastasis in breast cancer. These findings provide new insights into disease mechanisms and potential therapeutic targets.
A study of 2.5 million screening mammograms found improved detection of breast cancer from non-cancerous lesions over nine years, with increased recall rates and sensitivity rates. The increase in cancer detection outweighed false-positive test results, leading to a positive net effect.
A new study found that genome-wide association studies (GWA) have identified several genetic risk factors for common cancers, but their predictive power is limited by small effect sizes. The study suggests that performing GWA studies using larger sample sizes would yield more genetic loci with smaller or very small effects.
A study of over 10,000 breast cancer cases reveals the long-term prognosis for ER-negative disease subtypes is better than previously thought. The research also identifies two sub-types within triple negative tumors with differing outcomes.
A DNA-vaccine targeting DLL4 inhibits the formation of new blood vessels in tumours, leading to reduced tumour growth. The vaccine was shown to be effective in mice with breast cancer, causing a tightly packed network of non-functional blood vessels and poor blood supply.
A study in mice suggests that prenatal exposure to BPA or DES may program a fetus for life, increasing the risk of breast cancer in adulthood. Higher EZH2 levels are associated with an increased risk of breast cancer in humans, highlighting the potential need for monitoring women exposed to these chemicals.
Researchers have developed silica cages that can package anti-cancer antibodies, which significantly slow the growth of tumors and prolong the lives of mice. The treatment also reduces side effects compared to traditional intravenous drips.